The company is strategically expanding its product portfolio with a pipeline of new products that will form a strong foundation for future growth.
Revenues from operations for the full year ended March 31, 2022 stood at Rs. 590.05 crore as compared to Rs. 449.82 crore in FY21
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
The scope of supply includes the skid-mounted plant as well as on-site installation and commissioning support
Laxxon Medical has developed a 3D screen printing technology for the manufacture of structured tablets that enables the controlled release of active pharmaceutical ingredients over time
State-of-the-art laboratory to support ingredient and specialty chemical innovation, product formulation application development and more sustainable solutions across Europe and beyond
TRIS AMINO HCl is widely used as a diagnostic reagent and as a downstream processing buffer in the purification of commercial biopharmaceuticals
Subscribe To Our Newsletter & Stay Updated
